title: Phase II study of sunitinib as second-line treatment for advanced gastric cancer.
abstract: OBJECTIVE
  This phase II, open-label, multicenter study assessed the oral, multitargeted, tyrosine kinase inhibitor sunitinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma who had received prior chemotherapy.
  
  
  METHODS
  Patients received sunitinib 50 mg/day on Schedule 4/2 (4 weeks on treatment, followed by 2 weeks off treatment). The primary endpoint was objective response rate; secondary endpoints included clinical benefit rate, duration of response, progression-free survival (PFS), overall survival (OS), pharmacokinetics, pharmacodynamics, safety and tolerability, and quality of life.
  
  
  RESULTS
  Of 78 patients enrolled, most had gastric adenocarcinoma (93.6%) and metastatic disease (93.6%). All were evaluable for safety and efficacy. Two patients (2.6%) had partial responses and 25 patients (32.1%) had a best response of stable disease for ≥6 weeks. Median PFS was 2.3 months (95% confidence interval [CI], 1.6-2.6 months) and median OS was 6.8 months (95% CI, 4.4-9.6 months). Grade ≥ 3 thrombocytopenia and neutropenia were reported in 34.6% and 29.4% of patients, respectively, and the most common non-hematologic adverse events were fatigue, anorexia, nausea, diarrhea, and stomatitis. Pharmacokinetics of sunitinib and its active metabolite were consistent with previous reports. There were no marked associations between baseline soluble protein levels, or changes from baseline, and measures of clinical outcome.
  
  
  CONCLUSIONS
  The progression-delaying effect and manageable toxicity observed with sunitinib in this study suggest that although single-agent sunitinib has insufficient clinical value as second-line treatment for advanced gastric cancer, its role in combination with chemotherapy merits further study.
authors.affiliation: Department of Internal Medicine, Seoul National University College of Medicine, Yongon-Dong 28, Chongno-Gu, Seoul, 110-799, Republic of Korea. bangyj@snu.ac.kr
authors.forename: Yung-Jue
authors.initials: YJ
authors.lastname: Bang
authors.forename: Yoon-Koo
authors.initials: YK
authors.lastname: Kang
authors.forename: Won K
authors.initials: WK
authors.lastname: Kang
authors.forename: Narikazu
authors.initials: N
authors.lastname: Boku
authors.forename: Hyun C
authors.initials: HC
authors.lastname: Chung
authors.forename: Jen-Shi
authors.initials: JS
authors.lastname: Chen
authors.forename: Toshihiko
authors.initials: T
authors.lastname: Doi
authors.forename: Yan
authors.initials: Y
authors.lastname: Sun
authors.forename: Lin
authors.initials: L
authors.lastname: Shen
authors.forename: Shukui
authors.initials: S
authors.lastname: Qin
authors.forename: Wai-Tong
authors.initials: WT
authors.lastname: Ng
authors.forename: Jennifer M
authors.initials: JM
authors.lastname: Tursi
authors.forename: Maria J
authors.initials: MJ
authors.lastname: Lechuga
authors.forename: Dongrui Ray
authors.initials: DR
authors.lastname: Lu
authors.forename: Ana
authors.initials: A
authors.lastname: Ruiz-Garcia
authors.forename: Alberto
authors.initials: A
authors.lastname: Sobrero
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D018572:Disease-Free Survival; D004943:Esophagogastric Junction / Q000473:pathology; D005260:Female; D006801:Humans; D007211:Indoles / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D011758:Pyrroles / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011788:Quality of Life; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology; D000077210:Sunitinib; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; D047428:Protein Kinase Inhibitors; D011758:Pyrroles; D000077210:Sunitinib
references.citation: Anticancer Res. 2003 Sep-Oct;23(5b):4219-22
references.pmid: 14666628
references.citation: Br J Cancer. 2009 Jan 27;100(2):298-304
references.pmid: 19127259
references.citation: Ann Oncol. 1997 Feb;8(2):163-8
references.pmid: 9093725
references.citation: Mol Cancer Ther. 2003 May;2(5):471-8
references.pmid: 12748309
references.citation: J Clin Oncol. 2006 Oct 20;24(30):4922-7
references.pmid: 17050876
references.citation: Lancet. 2006 Oct 14;368(9544):1329-38
references.pmid: 17046465
references.citation: J Clin Oncol. 2006 Jun 20;24(18):2903-9
references.pmid: 16782930
references.citation: J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
references.pmid: 8433390
references.citation: Cancer Res Treat. 2009 Jun;41(2):100-3
references.pmid: 19707508
references.citation: J Clin Oncol. 2006 Sep 10;24(26):4309-16
references.pmid: 16963731
references.citation: Anticancer Drugs. 1999 Sep;10(8):729-33
references.pmid: 10573205
references.citation: CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108
references.pmid: 15761078
references.citation: Ann Surg. 1998 Mar;227(3):365-71
references.pmid: 9527059
references.citation: J Clin Oncol. 2006 Nov 20;24(33):5201-6
references.pmid: 17114652
references.citation: J Gastroenterol. 2008;43(4):256-64
references.pmid: 18458840
references.citation: Jpn J Clin Oncol. 2004 Jan;34(1):8-13
references.pmid: 15020657
references.citation: Clin Oncol (R Coll Radiol). 2005 Apr;17(2):81-90
references.pmid: 15830569
references.citation: Cancer. 1996 Mar 1;77(5):858-63
references.pmid: 8608475
references.citation: Ann Oncol. 2004 Nov;15(11):1585-95
references.pmid: 15520058
references.citation: J Korean Med Sci. 2007 Sep;22 Suppl:S5-S10
references.pmid: 17923755
references.citation: World J Gastroenterol. 2006 Jun 7;12(21):3297-305
references.pmid: 16733844
references.citation: J Clin Oncol. 2008 Apr 10;26(11):1810-6
references.pmid: 18347007
references.citation: Jpn J Clin Oncol. 2007 Dec;37(12):936-41
references.pmid: 18211985
references.citation: J Clin Oncol. 2007 May 1;25(13):1753-9
references.pmid: 17470865
references.citation: Clin Cancer Res. 2007 May 1;13(9):2643-50
references.pmid: 17473195
references.citation: Postgrad Med J. 2005 Jul;81(957):419-24
references.pmid: 15998815
references.citation: Ann Oncol. 2007 Mar;18(3):510-7
references.pmid: 17164226
references.citation: Blood. 2003 May 1;101(9):3597-605
references.pmid: 12531805
references.citation: Anticancer Drugs. 2006 Mar;17(3):353-8
references.pmid: 16520665
references.citation: World J Gastroenterol. 2002 Dec;8(6):994-8
references.pmid: 12439912
references.citation: N Engl J Med. 2007 Jan 11;356(2):115-24
references.pmid: 17215529
references.citation: Ann Oncol. 2007 Sep;18 Suppl 10:x11-9
references.pmid: 17761718
references.citation: World J Gastroenterol. 2007 Jul 14;13(26):3605-9
references.pmid: 17659711
references.citation: J Clin Oncol. 2008 Feb 1;26(4):650-6
references.pmid: 18235126
references.citation: Clin Cancer Res. 2003 Jan;9(1):327-37
references.pmid: 12538485
references.citation: Clin Cancer Res. 1996 Oct;2(10):1679-84
references.pmid: 9816116
references.citation: Expert Opin Pharmacother. 2007 Apr;8(6):797-808
references.pmid: 17425475
references.citation: J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
references.pmid: 10655437
references.citation: J Clin Oncol. 2006 Jan 1;24(1):16-24
references.pmid: 16330672
references.citation: Anticancer Res. 2007 Jul-Aug;27(4C):2667-71
references.pmid: 17695430
references.citation: Gastric Cancer. 2006;9(1):14-8
references.pmid: 16557431
references.citation: J Clin Oncol. 2006 Jan 1;24(1):25-35
references.pmid: 16314617
references.citation: Eur J Cancer. 2004 Oct;40(15):2260-8
references.pmid: 15454251